depression and tirzepatide Once-weekly subcutaneous was not associated with an increased risk of compared with placebo, according to a post hoc analysis of the SURMOUNT clinical trial programme. The findings were published in Study links semaglutide and tirzepatide

Pharmacokinetics parameters were calculated using DAS 2.0 software

JRNYS materials reference compounded semaglutide and compounded tirzepatide as options that may be discussed when clinically appropriate and legally available

Potential indirect mechanisms that could theoretically influence libido include: Nutritional deficiencies if caloric restriction is excessive Fatigue or low energy during the initial treatment phase Hormonal fluctuations associated with adipose tissue loss Psychological adjustment to body image changes Patients should be reassured that sexual side effects are not a recognised feature of Wegovy therapy, but any persistent concerns warrant clinical evaluation to exclude other contributing factors

You may be eligible for compensation

Escherichia coli D-malate dehydrogenase, a generalist enzyme active in the leucine biosynthesis pathway